Vericel (VCEL) Equity Average (2011 - 2026)
Vericel recorded quarterly Equity Average of $355.4 million in Q1 2026, up 5.08% quarter-over-quarter from $338.2 million in Q4 2025, and up 21.01% year-over-year from $293.7 million in Q1 2025.
Vericel's Equity Average history runs 16 years deep, the most recent figure standing at $355.4 million for Q1 2026.
- In Q1 2026, Equity Average rose 21.01% year-over-year to $355.4 million; the TTM figure through Mar 2026 stood at $355.4 million (up 21.01% YoY), while the FY2025 annual figure was $323.3 million, up 24.85% from the prior year.
- Equity Average came in at $355.4 million for Q1 2026 at Vericel, up from $338.2 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $355.4 million in Q1 2026 to a low of $171.5 million in Q1 2022.
- A 5-year average of $241.7 million and a median of $229.9 million in 2024 frame the typical range for Equity Average.
- Across the five-year window, Equity Average gained 12.63% in 2023 and advanced 27.75% in 2025, its largest moves.
- Vericel's Equity Average stood at $185.1 million in 2022, then increased by 16.27% to $215.2 million in 2023, then increased by 27.68% to $274.7 million in 2024, then advanced by 23.13% to $338.2 million in 2025, then increased by 5.08% to $355.4 million in 2026.
- According to Business Quant data, Equity Average over the past three periods registered $355.4 million, $338.2 million, and $314.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn | 355.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 355.44 Mn |
| Dec 31, 2025 | 338.25 Mn |
| Sep 30, 2025 | 314.33 Mn |
| Jun 30, 2025 | 301.15 Mn |
| Mar 31, 2025 | 293.73 Mn |
| Dec 31, 2024 | 274.72 Mn |
| Sep 30, 2024 | 250.22 Mn |
| Jun 30, 2024 | 238.44 Mn |
| Mar 31, 2024 | 229.92 Mn |
| Dec 31, 2023 | 215.17 Mn |
| Sep 30, 2023 | 201.65 Mn |
| Jun 30, 2023 | 196.45 Mn |
| Mar 31, 2023 | 193.13 Mn |
| Dec 31, 2022 | 185.05 Mn |
| Sep 30, 2022 | 176.33 Mn |
| Jun 30, 2022 | 173.65 Mn |
| Mar 31, 2022 | 171.47 Mn |
| Dec 31, 2021 | 163.62 Mn |
| Sep 30, 2021 | 153.94 Mn |
| Jun 30, 2021 | 145.65 Mn |
| Mar 31, 2021 | 137.23 Mn |
| Dec 31, 2020 | 124.45 Mn |
| Sep 30, 2020 | 111.11 Mn |
| Jun 30, 2020 | 109.02 Mn |
| Mar 31, 2020 | 110.77 Mn |
| Dec 31, 2019 | 104.04 Mn |
| Sep 30, 2019 | 92.77 Mn |
| Jun 30, 2019 | 95.80 Mn |
| Mar 31, 2019 | 102.64 Mn |
| Dec 31, 2018 | 98.35 Mn |
| Sep 30, 2018 | 92.54 Mn |
| Jun 30, 2018 | 55.77 Mn |
| Mar 31, 2018 | 21.74 Mn |
| Dec 31, 2017 | 19.64 Mn |
| Sep 30, 2017 | 15.36 Mn |
| Jun 30, 2017 | 14.74 Mn |
| Mar 31, 2017 | 20.11 Mn |
| Dec 31, 2016 | 18.05 Mn |
| Sep 30, 2016 | 14.25 Mn |
| Jun 30, 2016 | 18.17 Mn |
| Mar 31, 2016 | 20.68 Mn |
| Dec 31, 2015 | 24.27 Mn |
| Sep 30, 2015 | 28.33 Mn |
| Jun 30, 2015 | 30.97 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Dec 31, 2014 | 36.71 Mn |
| Sep 30, 2014 | 20.28 Mn |
| Jun 30, 2014 | 3.28 Mn |
| Mar 31, 2014 | 3.83 Mn |
| Dec 31, 2013 | 4.42 Mn |
| Sep 30, 2013 | -18.04 Mn |
| Jun 30, 2013 | -38.80 Mn |
| Mar 31, 2013 | -34.34 Mn |
| Dec 31, 2012 | -28.37 Mn |
| Sep 30, 2012 | -22.67 Mn |
| Jun 30, 2012 | -21.22 Mn |
| Mar 31, 2012 | -17.35 Mn |
| Dec 31, 2011 | -12.06 Mn |
| Sep 30, 2011 | -10.66 Mn |